| Gastroenterology Research, ISSN 1918-2805 print, 1918-2813 online, Open Access |
| Article copyright, the authors; Journal compilation copyright, Gastroenterol Res and Elmer Press Inc |
| Journal website http://www.gastrores.org |
Review
Volume 4, Number 3, June 2011, pages 93-96
Fidaxomicin for the Treatment of Clostridium Difficile Infection in the Pediatric Population - Not Quite So Soon Yet
Tables
| Absorption | Very poor |
| Distribution | Plasma concentration low (< 5 mcg/ml) Fecal concentration very high (1443.3 mcg/g) |
| Metabolism | No systemic metabolism Forms fecal active metabolite |
| Excretion | Fecal Urine concentrations undetectable |
| Half Life | 0.94 - 2.77 hours |
| Intention to Treat | Per Protocol | |||
|---|---|---|---|---|
| Fidaxomicin | Vancomycin | Fidaxomicin | Vancomycin | |
| *Clinical cure = resolution of symptoms and no need for further treatment of C difficile infection as of the second day after the end of the course of therapy | ||||
| **Recurrence = diarrhea and a positive result on a stool toxin test within 4 weeks after treatment. | ||||
| ***Global cure = cure with no recurrence. | ||||
| Clinical Cure* | 88.2% (253/287) | 85.8% (265/309) | 92.1% (244/265) | 89.8% (254/283) |
| Recurrence** | 15.4% (39/253) | 25.3% (67/265) | 13.3% (28/211) | 24.0% (53/221) |
| Global Cure*** | 71.6% (214/287) | 64.1% (198/309) | 77.7% (206/265) | 67.1% (190/283) |